Tag: FDA bioequivalence
FDA Bioequivalence Standards for NTI Drugs: Special Requirements Explained
The FDA enforces stricter bioequivalence standards for narrow therapeutic index (NTI) drugs like warfarin, digoxin, and phenytoin, requiring tighter limits (90-111%) and replicate studies to ensure patient safety. These rules prevent dangerous fluctuations in blood levels that can occur with generics.